Research ExplorerPublicationsSecukinumab demonstrates high and sustained efficacy in nail...

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Standard

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. / Reich, Kristian; Baraliakos, Xenophon; Coates, Laura C; Elewski, Boni; Bao, Weibin; Kasparek, Torben; Gaillez, Corine; Pournara, Effie; Aassi, Maher; Perella, Chiara; Gottlieb, Alice B.

In: BRIT J DERMATOL, Vol. 187, No. 3, 09.2022, p. 438-441.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Reich, K, Baraliakos, X, Coates, LC, Elewski, B, Bao, W, Kasparek, T, Gaillez, C, Pournara, E, Aassi, M, Perella, C & Gottlieb, AB 2022, 'Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis', BRIT J DERMATOL, vol. 187, no. 3, pp. 438-441. https://doi.org/10.1111/bjd.21233

APA

Reich, K., Baraliakos, X., Coates, L. C., Elewski, B., Bao, W., Kasparek, T., Gaillez, C., Pournara, E., Aassi, M., Perella, C., & Gottlieb, A. B. (2022). Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. BRIT J DERMATOL, 187(3), 438-441. https://doi.org/10.1111/bjd.21233

Vancouver

Reich K, Baraliakos X, Coates LC, Elewski B, Bao W, Kasparek T et al. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. BRIT J DERMATOL. 2022 Sep;187(3):438-441. https://doi.org/10.1111/bjd.21233

Bibtex

@article{278f7d2b062d4092a08a43a549777ba8,
title = "Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis",
abstract = "Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.",
keywords = "Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic/complications, Humans, Nail Diseases/complications, Nails, Malformed, Psoriasis/complications, Severity of Illness Index",
author = "Kristian Reich and Xenophon Baraliakos and Coates, {Laura C} and Boni Elewski and Weibin Bao and Torben Kasparek and Corine Gaillez and Effie Pournara and Maher Aassi and Chiara Perella and Gottlieb, {Alice B}",
note = "{\textcopyright} 2022 British Association of Dermatologists.",
year = "2022",
month = sep,
doi = "10.1111/bjd.21233",
language = "English",
volume = "187",
pages = "438--441",
journal = "BRIT J DERMATOL",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

AU - Reich, Kristian

AU - Baraliakos, Xenophon

AU - Coates, Laura C

AU - Elewski, Boni

AU - Bao, Weibin

AU - Kasparek, Torben

AU - Gaillez, Corine

AU - Pournara, Effie

AU - Aassi, Maher

AU - Perella, Chiara

AU - Gottlieb, Alice B

N1 - © 2022 British Association of Dermatologists.

PY - 2022/9

Y1 - 2022/9

N2 - Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.

AB - Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.

KW - Antibodies, Monoclonal, Humanized

KW - Arthritis, Psoriatic/complications

KW - Humans

KW - Nail Diseases/complications

KW - Nails, Malformed

KW - Psoriasis/complications

KW - Severity of Illness Index

U2 - 10.1111/bjd.21233

DO - 10.1111/bjd.21233

M3 - Other (editorial matter etc.)

C2 - 35257363

VL - 187

SP - 438

EP - 441

JO - BRIT J DERMATOL

JF - BRIT J DERMATOL

SN - 0007-0963

IS - 3

ER -